glp-1 drugs fda approved for weight loss Wegovy Pill Wins Approval as First Oral Treatment Obesity and GLP-1 weight loss drugs are

Body composition and metabolic changes following 12 months of semaglutide 2.4 mg in adults with obesity: a prospective study

GLP-1 receptor agonists also have favourable effects on albuminuria and may slow eGFR decline , though the evidence for hard renal outcomes is less robust than for SGLT2 inhibitors

Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats

Investigational glucagon-like peptide-1 agonists for the treatment of obesity

doi: 10.1345/aph.1H060 121 HeimburgerSMBrondenAJohansenNJDejgaardTFVilsbollTKnopFK

If there is a rebound weight, we have a problem, because we're going to create the same problems that we started with, says Pinto